Fmo2-KO Mouse
一般名
Fmo2-KO
製品ID
S-KO-19413
背景情報
C57BL/6JCya
系統ID
KOCMP-55990-Fmo2-B6J-VC
状況
このマウス系統を論文で使用する場合は、「Fmo2-KO Mouse(カタログ番号S-KO-19413)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Fmo2-KO
系統ID
KOCMP-55990-Fmo2-B6J-VC
遺伝子名
製品ID
S-KO-19413
遺伝子別名
2310008D08Rik, 2310042I22Rik
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 1
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000045902
NCBIトランスクリプトID
NM_018881
ターゲット領域
Exon 4
有効領域の大きさ
~0.8 kb
遺伝子研究の概要
Fmo2, or flavin-containing monooxygenase 2, is involved in multiple biological processes and disease-related pathways. It has been shown to play roles in processes such as lipogenesis regulation, immune-related responses, and cell protection mechanisms. Genetic models, like gene knockout (KO) and conditional knockout (CKO) mouse models, have been crucial for studying its functions [1,3,5].
In the context of non-alcoholic fatty liver disease (NAFLD), both global and hepatocyte-specific knockout of Fmo2 in mice led to increased lipogenesis, severe hepatic steatosis, inflammation, and fibrosis. In contrast, FMO2 overexpression improved NAFL/NASH. Mechanistically, FMO2 directly interacts with SREBP1, inhibiting its translocation from the endoplasmic reticulum to the Golgi apparatus and subsequent activation, thus suppressing de novo lipogenesis [1].
In epithelial ovarian cancer, FMO2 is upregulated in tumor stroma, correlates with fibroblast activation, and predicts a worse clinical outcome. It also contributes to immune cell infiltration, especially of CD163 + macrophages [2].
In the heart, genetic deletion of FMO2 in cardiomyocytes reduced cell survival and enhanced cardiac dysfunction after ischemic injury, while cardiomyocyte-specific overexpression had a protective effect. FMO2 inhibits ER stress-induced apoptotic proteins through its disulfide bond catalytic activity [3].
In breast cancer, FMO2 is downregulated and is closely related to clinical indicators. Decreased FMO2 expression is associated with poor survival, and it may be related to immunotherapy sensitivity [4].
In post-myocardial infarction cardiac remodeling, CELF1 promotes remodeling by suppressing FMO2, and FMO2 overexpression can improve extracellular matrix deposition and cardiac remodeling [5].
In lung adenocarcinoma, circ_MACF1 upregulates FMO2 by targeting miR-421, suppressing paclitaxel resistance and malignant cellular behaviors [6].
In conclusion, Fmo2 plays essential roles in various biological processes and disease conditions. Studies using KO/CKO mouse models have revealed its significance in diseases such as NAFLD, epithelial ovarian cancer, ischemic heart disease, breast cancer, post-myocardial infarction cardiac remodeling, and lung adenocarcinoma. Understanding Fmo2 functions provides insights into disease mechanisms and potential therapeutic targets.
References:
1. Ke, Changle, Xiao, Changchen, Li, Jiamin, Wu, Rongrong, Hu, Xinyang. 2023. FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1. In Hepatology (Baltimore, Md.), 81, 181-197. doi:10.1097/HEP.0000000000000643. https://pubmed.ncbi.nlm.nih.gov/37874228/
2. Yu, Sihui, Yang, Rui, Xu, Tianhan, Wu, Sufang, Zhang, Jiawen. 2022. Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer. In Gynecologic oncology, 167, 342-353. doi:10.1016/j.ygyno.2022.09.003. https://pubmed.ncbi.nlm.nih.gov/36114029/
3. Liu, Qingnian, Huang, Jiniu, Ding, Hao, Hu, Xinyang, Wang, Jian'an. 2024. Flavin-containing monooxygenase 2 confers cardioprotection in ischemia models through its disulfide bond catalytic activity. In The Journal of clinical investigation, 134, . doi:10.1172/JCI177077. https://pubmed.ncbi.nlm.nih.gov/39480513/
4. Wu, Lichun, Chu, Jie, Shangguan, Lijuan, Cao, Mingfei, Lu, Feng. 2023. Discovery and identification of the prognostic significance and potential mechanism of FMO2 in breast cancer. In Aging, 15, 12651-12673. doi:10.18632/aging.205204. https://pubmed.ncbi.nlm.nih.gov/37963835/
5. Lai, Jun, Li, Likang, Liu, Jun, Jin, Wen, Ye, Zebing. 2025. CELF1 Promotes Post-myocardial Infarction Cardiac Remodeling Via Suppression of FMO2. In Cardiovascular toxicology, 25, 441-454. doi:10.1007/s12012-024-09951-5. https://pubmed.ncbi.nlm.nih.gov/40021568/
6. Qian, Xiaoting, Chen, Chunhua, Tong, Sanxiang, Zhang, Jun. 2023. Circ_MACF1 targets miR-421 to upregulate FMO2 to suppress paclitaxel resistance and malignant cellular behaviors in lung adenocarcinoma. In Thoracic cancer, 14, 3348-3357. doi:10.1111/1759-7714.15132. https://pubmed.ncbi.nlm.nih.gov/37814902/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
